Guardant raises FY2026 revenue guidance to $1.36B-$1.37B while targeting Shield cost per test of $200 by end of 2028 (NASDAQ:GH)
Guardant Health (GH) reported Q3 2026 revenue of $361M, up 36% YoY. Oncology revenue grew 25% YoY. The company raised FY2026 revenue guidance to $1.36B-$1.37B and aims for a Shield test cost of $200 by 2028.
How this was made
The 30-second read
Why it matters
The guidance raise is a primary disclosure that can shift valuation metrics.
Market read
New revenue guidance and cost target provide fresh material for traders to adjust positions.
What to watch
Potential competitive pressure from emerging diagnostics platforms.
Background
Guardant Health disclosed Q3 2026 results and FY2026 guidance in an earnings call.
Ticker impact
Guardant Health raised FY2026 revenue guidance to $1.36B-$1.37B and set a target Shield test cost of $200 by 2028.
upward pressure as investors price in higher revenue outlook and margin improvement
Revenue guidance increase of ~5% and cost reduction target are material new data that can move the share price immediately.
Market effects
Positive for liquid biopsy and cancer diagnostics sector, may lift peers.
U.S. biotech market could see modest upside.
Limited to healthcare investors, no broad macro effect.
Counterpoint
Guidance may be optimistic; execution risk on cost target could disappoint.
Key entities
- companyGuardant Health
Liquid biopsy company listed on NASDAQ under ticker GH.
